Previous close | 9.90 |
Open | N/A |
Bid | 11.80 |
Ask | 13.30 |
Strike | 25.00 |
Expiry date | 2024-08-16 |
Day's range | 9.90 - 9.90 |
Contract range | N/A |
Volume | |
Open interest | 23 |
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.